Arbeitsgruppe Thorakale Onkologie - Studien
| ALK+ NSCLC | ||||
| AIO-Studie | zur Studie | |||
| AIO-TRK-0219: Advancing Brigatinib Properties in anaplastic lymphoma kinase positive non-small cell lung cancer (ALK+ NSCLC) patients by deep phenotyping (APB-Trial) | ||||
| ---in Vorbereitung--- | ||||
| NSCLC Stage III |
||||
| AIO-Studie | zur Studie | |||
| AIO-YMO/TRK-0319: Thoracic Radiotherapy plus Durvalumab in Elderly - Employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy (TRADEhypo) | ||||
| ---in Vorbereitung--- | ||||
| Stage IV SCLC | ||||
| AIO-Studie | zur Studie | |||
| AIO-TRK-0119: Single-Arm Phase II-Study in Patients with extensive stage small cell lung cancer (ES-SCLC) with Poor Performance Status receiving Atezolizumab-Carboplatin-Etoposide (SPACE) | ||||
| ---in Vorbereitung--- | ||||
| NSCLC mit EGFR-Mutation |
| AIO-Studie | www.clinicaltrials.gov |
zur Studie | ||
| AIO-TRK-0216: An open-label, multicenter, phase I dose-escalation trial of EGF816 and trametinib in patients with non-small cell lung cancer and acquired EGFR p.T790M positive resistance to 1st or 2nd generation EGFR TKI therapy (EATON-Trial) |
||||
| ---in Rekrutierung--- | ||||
| Metastatic non-small cell lung cancer (NSCLC) |
| AIO-Studie | www.clinicaltrials.gov | zur Studie | ||
| AIO-YMO/TRK-0416: DURvalumab (MEDI4736) in frAil and elder PaTIents with metastatic Nsclc [DURATION] | ||||
| ---in Rekrutierung--- | ||||
| Metastatic adenocarcinoma of the lung (non-squamousNSCLC), second line and beyond |
| AIO-Studie | www.clinicaltrials.gov | zur Studie | ||
| AIO-YMO/TRK-0415: Fostering efficacy of anti – PD-1 – treatment: Nivolumab plus radiotherapy in advanced NSCLC [FORCE in NSCLC] | ||||
| ---in Rekrutierung--- | ||||
| NSCLC und SCLC second line |
| AIO-Studie | www.clinicaltrials.gov | zur Studie | ||
| AIO-TRK-0116: Eine Phase II-Studie mit Nivolumab in Kombination mit Ipilimumab zur Evaluierung der Sicherheit und Wirksamkeit im rezidivierten Lungenkrebs und zur Evaluierung von Biomarkern welche für das Ansprechen auf Immuncheckpointinhibition prädiktiv sind (BIOLUMA) |
||||
| ---in Rekrutierung--- | ||||
| NSCLC, second line | ||||
| AIO-Studie | zur Studie | |||
| AIO-TRK-0117: Machbarkeit und Sicherheit von Nintedanib in Kombination mit Nivolumab bei vorbehandelten Patienten mit fortgeschrittenem oder metastasiertem nicht-kleinzelligem Lungenkarzinom (NSCLC) mit Adenokarzinom-Histologie - Eine AIO-Phase-Ib-Studie (NintNivo) | ||||
| ---in Rekrutierung--- | ||||
| AIO-Studie | zur Studie | |||
| AIO-TRK/YMO-0419: Nivolumab with chemotherapy in pleural mesothelioma after surgery (NICITA) | ||||
| ---in Vorbereitung--- | ||||
| AIO-Studie | weitere Zentren erwünscht | zur Studie | ||
| AIO-YMO/TRK-0120: Radiation during Osimertinib Treatment: a Safety and Efficacy Cohort Study (ROSE) | ||||
| ---in Vorbereitung--- | ||||
| Registerstudie NSCLC | ||||
| AIO-Studie | weitere Zentren auf Anfrage |
www.clinicaltrials.gov | zur Studie | |
| AIO-TRK-0315: Clinical Research Platform Into Molecular Testing, Treatment and Outcome of Non-Small Cell Lung Carcinoma Patients (CRISP)) | ||||
| ---in Rekrutierung--- | ||||
| Pressemitteilung vom 16.05.2017 | ||||
| LETZTE AKTUALISIERUNG DIESER SEITE AM: 08.05.2020 |